Biphasic effect of lignanoid decomposition products:enterolactone and enterodiol on osteoblast-like MG63 cells

Abstract

Abstract: AIM: To observe the effects of enterodiol and enterolactone on osteoblastic MG63 cells.METHODS: The effects of enterodiol and enterolactone on the proliferation of MG63 cells were observed by MTT. The effects of enterodiol and enterolactone on the activity of MG63 cells were tested by alkaline phosphatase(ALP)test. The effects of enterodiol and enterolactone on transcriptional level of a ALP,osteocalcin, and collagenⅠof MG63 cells were measured by RT-PCR.RESULTS: The cell viability of MG63 cells significantly was increased when treated with 0.01 mg/mL enterolactone or enterodiol.The viability of MG63 cells was gradually weakened with the increase of concentration.Similar to their effects on the cell viability of MG63 cells, enterolactone or enterodiol increased the ALP activity of MG63 cells at low concentration and decreased the ALP activity at high concentration. Enterolactone or enterodiol can increase the transcriptional level of ALP, collagenⅠ,and osteocalcin in MG63 cells.CONCLUSION: The osteoblast cells viability is increased at low concentration treated with enterolactone and enterodiol, but that is decreased at high concentration.Enterolactone and enterodiol have biphasic effect on MG63 cells.

Key words: Lignanoid, Enterolactone, Enterodiol, MG63 , , , ,

CLC Number:

R965.2

LI Gao-shun,YE Zhao-ming,YANG Di-sheng. Biphasic effect of lignanoid decomposition products:enterolactone and enterodiol on osteoblast-like MG63 cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(1): 46-50.

References

[1] Netelenbos C. Osteoporosis: intervention options[J]. Maturitas, 1998, 30(3):235-239.
[2] Gallagher JC. Moderation of the daily dose of HRT: prevention of osteoporosis[J]. Maturitas, 1999,33: 57-63.
[3] Chiechi LM. Dietary phytoestrogens in the prevention of long-term postmenopausal diseases[J]. Int J Gynecol Obstet, 1999,67(1):39-40.
[4] Wuttke W, Jarry H, Westphalen S. et al. Phytoestrogens for hormone replacement therapy[J]? J Steroid Biochem Mol Biol,2002, 83(1/2/3/4/5):133-147.
[5] Anderson JJ, Anthony M, Messina M, et al. Effects of phyto-oestrogen on tissues[J]. Nutr Res Rev, 1999,12(1): 75-116.
[6] Brzezinski A, Debi A. Phytoestrogens: the “natural” selective estrogen receptor modulators[J]? Eur J Obstet Gynecol Reprod Biol ,1999,85(1): 47-51.
[7] 商敏,杨欣,李亚珍,等.异普黄酮抗卵巢切除大鼠的骨质疏松与上调腰椎护骨素mRNA的表达[J]. 中国临床药理学与治疗学,2006,11(10):1173-1176.
[8] 姚莹,李昌煜,林婷.五味子藤茎中木脂素对四氯化碳致小鼠急性肝损伤的保护作用[J]. 中国临床药理学与治疗学,2010,15(9):978-982.
[9] Brooks JD, Ward WE, Lewis JE, et al. Supplementation with flaxseed alters estrogen metabolism in postmenopausal women to a greater extent than does supplementation with an equal amount of soy[J]. Am J Clin Nutr , 2004, 79(2):318-325.
[10]Anderson JJ, Ambrose WW, Garner SC. Biphasic effects of genistein on bone tissue in the ovariectomized, lactating rat model[J]. Proc Soc Exp Biol Med,1998, 217(3):345-350.
[11]Chen LH, Fang J, Li H, et al. Enterolactone induces apoptosis in human prostate carcinoma LNCaP cells via a mitochondrial-mediated, caspase-dependent pathway[J]. Mol Cancer Ther,2007,6(9):2581-2590.
[12]Prasad K. Antioxidant Activity of Secoisolariciresinol Diglucoside-derived Metabolites, Secoisolariciresinol, Enterodiol and Enterolactone[J]. Int J Angiol,2000,9(4):220-225.

[1]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[2]	WANG Kun, XU Peipei, ZHOU Lanlan, LU Sheng. Mechanism of neuroprotective effect of ginsenoside Rg1 regulating Epac1/Rap1 signaling pathway in rats with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 721-727.
[3]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[4]	LI Hongqin, CAO Limin, JIN Manyi, WANG Jianlong, CHAI Xiaoping, TIAN Miaomiao. Effects of different dosage forms of Qianzheng powder on facial nerve injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 617-623.
[5]	WU Xiongzhi, WANG Xuan, XU Siqi, JU Xia, WANG Shengbin, CHEN Yongquan. A comparative investigation of the impact of oral midazolam solution and dexmedetomidine nasal spray on preoperative anxiety in pediatric patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 666-670.
[6]	CAI Zuhuan, DENG Taomei, WEI Naijie, ZHU Dan, QIAN Fei, WANG Guangji, ZHANG Jingwei. Silybin ameliorates lipid metabolism disorders in mice with non-alco-holic steatohepatitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 241-248.
[7]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[8]	LUO Mingjie, LIU Runhan, ZHOU Jie, WANG Zhenlei. Comparison of common parameter estimation methods in NONMEM 7.5.1.: A case study of ibuprofen injection in Chinese healthy adult population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 290-298.
[9]	WU Zhiyong, LIU Bingrong, LI Bin, TANG Rui. Value of red blood cell distribution width in predicting early poor neurologic improvement after intravenous thrombolysis in patients with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 307-314.
[10]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[11]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[12]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[13]	HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50.
[14]	PANG Shengfeng, ZHANG Jing, WU Ningning, LI Ru, CAO Jun, HE Shenghu. Efficacy of antiplatelet therapy with ticagrelor monotherapy after short-term double antibody therapy in patients with acute coronary syndrome after PCI [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1004-1009.
[15]	WANG Kai, SONG Min, SONG Zhijing, LI Jinyi. Mechanism of vascular endothelial cells ferroptosis in cervical spondylosis of vertebral artery type [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 588-594.